Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 3Genitourinary 3Gynecologic 2CNS 2Tumor-Agnostic 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma, Endometrial Stromal 1Ovarian Neoplasms 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 87Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 31Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × trebananib × Gynecologic × Clear all
NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Dana-Farber Cancer Institute

Phase 1 Completed
62 enrolled 17 charts
DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT01210222 2018-02-23

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

GOG Foundation

Phase 2 Completed
35 enrolled 9 charts
GynecologicSarcoma

Sarcoma, Endometrial Stromal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡